New Denodo Platform 8.0 Accelerates Hybrid/Multicloud Integration, Automates Data Management with AI/ML, and Boosts Performance
30.9.2020 09:00:00 EEST | Business Wire | Press release
Denodo, the leader in data virtualization, today announced that its new Denodo Platform version 8.0 accelerates hybrid/multicloud integration, automates data management with artificial intelligence (AI)/machine learning (ML), and boosts performance with smart query acceleration. By further augmenting the Denodo Platform’s already advanced data integration, management, and delivery capabilities with intelligent recommendations, hyper performance, and PaaS support, Denodo Platform 8.0 advances data virtualization into a logical data fabric.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005427/en/
“Data fabric is a hot, emerging market that delivers a unified, intelligent, and integrated end-to-end platform to support new and emerging use cases,” wrote Noel Yuhanna, VP and principal analyst at Forrester Research, and author of The Forrester WaveTM: Enterprise Data Fabric, Q2 2020. The report also states, “Denodo is known for data virtualization, and over the years it has also evolved into a data fabric vendor. Denodo’s data fabric solution integrates key data management components, including data integration, data ingestion, data transformation, data governance and security, to support new and emerging use cases including customers 360, real-time and on-demand analytics, IoT analytics, and self-service analytics. In addition, Denodo’s AI/ML capabilities, as well as automation, continue to enhance its capabilities across data fabric components.”
Through data virtualization, the Denodo Platform offers enterprise-grade data integration, management, and delivery that rivals legacy data integration techniques. The new version of the Denodo Platform advances agile data integration and governed data management, extending Denodo’s reach into advanced hybrid and multicloud architectures and new data science use cases.
“Denodo 8.0 packs key capabilities that are essential for our Decision Support Initiative,” said Dan Young, chief data architect and manager at Indiana University, Bloomington. “Our mission is to provide timely, relevant, and accurate data for better decision making to our executives and faculty. The Denodo Platform has been a key technology in our logical data fabric architecture, integrating student and enrollment, personnel, and financial data, and delivering the unified information to our Academics Metrics (AM) 360 dashboards. With it, decision makers at Indiana University have been able to successfully measure, compare, and analyze trends regarding the health of their responsibility centers.”
Key functionalities of Denodo Platform 8.0 include:
- Hybrid cloud/multicloud integration: Denodo Platform 8.0 enables organizations to accelerate data integration across different locations while lowering operational costs and leveraging platform-as-a-service (PaaS)-style infrastructure automation and autoscaling support.
- Machine learning/data science automation: An ML-aided data catalog helps data scientists discover and prepare data for building complex data models and aids in supporting advanced analytics. With the integrated Apache Zeppelin Notebook, they can construct narratives combining queries with code, text, and graphics, and share it with fellow data scientists.
- API/microservices enhancements: New support for execution of GraphQL on top of logical data models promotes no-code approach to the use of REST APIs and accelerates the adoption of advanced microservices architectures.
- Hyper performance: Denodo Platform 8.0 maximizes query delegation and boosts performance to sub-second responses with AI-powered recommendations, advanced caching, and smart query acceleration for frequent, expensive queries.
- Unified Web-based UI with Single Sign-On: Newly introduced interface unifies all design and runtime tools with single sign-on support facilitating rapid design, development, deployment, and management processes.
“Denodo 8.0 is the result of years of continuous innovation to support our customers’ enterprise data management journeys,” said Alberto Pan, executive vice president and chief technology officer at Denodo. “Our customers have been pioneers in their respective industries, leveraging the Denodo Platform as the enterprise logical data fabric for advanced analytics, cloud modernization, data science, and data services. We responded to our customers’ requests by providing the most advanced data platform in the industry with PaaS-style infrastructure management, machine learning data catalog, GraphQL support, smart query acceleration, and an easy-to-use unified user interface.”
Recently, Denodo was named a Leader in the 2020 Gartner Magic Quadrant for Data Integration Tools.
Please Tweet: News: @denodo announces new Denodo Platform 8.0. Latest version supports advanced #DataVirtualization #DataFabric #HybridCloud #Multicloud #ML #AI #Microservices capabilities.
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, and cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005427/en/
Contact information
Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
